Pebxx.Ax

The company's capital structure is characterized by a low debt-to-equity ratio of 0.11, indicating a conservative leverage position. However, the liquidity risk is assessed as low, and the current ratio of 3.16 suggests the company has sufficient short-term assets to cover its liabilities. Despite this, the operating cash flow of -24.74 million NZD and free cash flow of -28.39 million NZD indicate significant cash outflows, which could impact the company's ability to fund operations without external financing.

Profitability metrics are concerning, with a return on equity of -114.76% and a return on assets of -80.84%. These figures are well below the industry norms for biotechnology and medical research firms, which typically require high R&D investment and long development cycles before achieving profitability. The company reported a net loss of 29.94 million NZD and an operating loss of 31.77 million NZD, highlighting the challenges it faces in generating positive returns.

The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification. This lack of diversification increases the risk associated with market-specific downturns or regulatory changes. The absence of segment-specific revenue data makes it difficult to assess the performance of individual product lines or geographic regions.

The company's growth trajectory is uncertain, with no disclosed revenue growth rates or future projections. The operating and net losses suggest that the company is not currently generating sufficient revenue to cover its costs, let alone invest in growth initiatives. Analysts have provided a mean price target of 0.12 NZD, with a median of 0.12 NZD, indicating limited upside potential in the near term.

Risk factors include the company's negative cash flows and the inability to assess dilution risk due to missing share count data. The company's reliance on external financing to fund operations increases the risk of dilution for existing shareholders. Additionally, the lack of detailed information on R&D pipelines and product development timelines limits visibility into future growth opportunities.

Recent events include the publication of the latest financial data, which shows continued losses and negative cash flows. There are no recent filings or transcripts indicating significant changes in the company's strategy or operations. The absence of strong buy or buy recommendations from analysts further underscores the cautious outlook for the company.